Terms: = Prostate cancer AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID
102 results:
1. Infiltrating immune cells in prostate cancer tissue after androgen deprivation and radiotherapy.
Erlandsson A; Lundholm M; Watz J; Bergh A; Petrova E; Alamdari F; Helleday T; Davidsson S; Andren O; Tarish F
Int J Immunopathol Pharmacol; 2023; 37():3946320231158025. PubMed ID: 36880147
[TBL] [Abstract] [Full Text] [Related]
2. Deletion of monoamine oxidase A in a prostate cancer model enhances anti-tumor immunity through reduced immune suppression.
Lapierre JA; Geary LA; Jang JK; Epstein AL; Hong F; Shih JC
Biochem Biophys Res Commun; 2022 Dec; 634():100-107. PubMed ID: 36242915
[TBL] [Abstract] [Full Text] [Related]
3. prostate Infiltration by Treg and Th17 Cells as an Immune Response to
Radej S; Szewc M; Maciejewski R
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012113
[TBL] [Abstract] [Full Text] [Related]
4. A New Promising Pathway in Aggressive prostate cancer: Treg/mir-let8c/lin28b.
Akalin I; Erol B; Aslan E; Ozkanli SS; Efiloglu O; Yildirim S; Caskurlu T; Yildirim A; Karaman MI
Arch Esp Urol; 2022 Jun; 75(5):459-466. PubMed ID: 35983819
[TBL] [Abstract] [Full Text] [Related]
5. Immune Evasion and Drug Resistance Mediated by USP22 in cancer: Novel Targets and Mechanisms.
Guo J; Zhao J; Fu W; Xu Q; Huang D
Front Immunol; 2022; 13():918314. PubMed ID: 35935969
[TBL] [Abstract] [Full Text] [Related]
6. Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype.
van Wilpe S; Simnica D; Slootbeek P; van Ee T; Pamidimarri Naga S; Gorris MAJ; van der Woude LL; Sultan S; Koornstra RHT; van Oort IM; Gerritsen WR; Kroeze LI; Simons M; van Leenders GJLH; Binder M; de Vries IJM; Mehra N
Oncoimmunology; 2022; 11(1):2094133. PubMed ID: 35800157
[TBL] [Abstract] [Full Text] [Related]
7. Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.
Mendes AA; Lu J; Kaur HB; Zheng SL; Xu J; Hicks J; Weiner AB; Schaeffer EM; Ross AE; Balk SP; Taplin ME; Lack NA; Tekoglu E; Maynard JP; De Marzo AM; Antonarakis ES; Sfanos KS; Joshu CE; Shenderov E; Lotan TL
Cancer; 2022 Jun; 128(12):2269-2280. PubMed ID: 35333400
[TBL] [Abstract] [Full Text] [Related]
8. Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer.
Kaur HB; Vidotto T; Mendes AA; Salles DC; Isaacs WB; Antonarakis ES; Lotan TL
Cancer Immunol Immunother; 2022 Apr; 71(4):943-951. PubMed ID: 34533610
[TBL] [Abstract] [Full Text] [Related]
9. B7 score and T cell infiltration stratify immune status in prostate cancer.
Zhou Q; Li K; Lai Y; Yao K; Wang Q; Zhan X; Peng S; Cai W; Yao W; Zang X; Xu K; Huang J; Huang H
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34417325
[TBL] [Abstract] [Full Text] [Related]
10. Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors.
Andersen LB; Nørgaard M; Rasmussen M; Fredsøe J; Borre M; Ulhøi BP; Sørensen KD
J Pathol; 2021 Oct; 255(2):155-165. PubMed ID: 34255349
[TBL] [Abstract] [Full Text] [Related]
11. Construction of enzalutamide-resistant cell model of prostate cancer and preliminary screening of potential drug-resistant genes.
Feng T; Wei D; Zhao J; Li Q; Guo P; Yang X; Li M; Jiang Y; Luo Y
Exp Biol Med (Maywood); 2021 Aug; 246(15):1776-1787. PubMed ID: 34034559
[TBL] [Abstract] [Full Text] [Related]
12. Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity.
Sturgill ER; Rolig AS; Linch SN; Mick C; Kasiewicz MJ; Sun Z; Traber PG; Shlevin H; Redmond WL
Oncoimmunology; 2021 Mar; 10(1):1892265. PubMed ID: 33717655
[TBL] [Abstract] [Full Text] [Related]
13. Caloric Restriction Impairs Regulatory T cells Within the Tumor Microenvironment After Radiation and Primes Effector T cells.
Manukian G; Kivolowitz C; DeAngelis T; Shastri AA; Savage JE; Camphausen K; Rodeck U; Zarif JC; Simone NL
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1341-1349. PubMed ID: 33647370
[TBL] [Abstract] [Full Text] [Related]
14. The role of regulatory T cells in the pathogenesis and treatment of prostate cancer.
Karpisheh V; Mousavi SM; Naghavi Sheykholeslami P; Fathi M; Mohammadpour Saray M; Aghebati-Maleki L; Jafari R; Majidi Zolbanin N; Jadidi-Niaragh F
Life Sci; 2021 Nov; 284():119132. PubMed ID: 33513396
[TBL] [Abstract] [Full Text] [Related]
15.
Lotan TL; Antonarakis ES
Clin Cancer Res; 2021 Jan; 27(2):380-382. PubMed ID: 33199495
[TBL] [Abstract] [Full Text] [Related]
16. Characterizing CDK12-Mutated prostate cancers.
Rescigno P; Gurel B; Pereira R; Crespo M; Rekowski J; Rediti M; Barrero M; Mateo J; Bianchini D; Messina C; Fenor de la Maza MD; Chandran K; Carmichael J; Guo C; Paschalis A; Sharp A; Seed G; Figueiredo I; Lambros M; Miranda S; Ferreira A; Bertan C; Riisnaes R; Porta N; Yuan W; Carreira S; de Bono JS
Clin Cancer Res; 2021 Jan; 27(2):566-574. PubMed ID: 32988971
[TBL] [Abstract] [Full Text] [Related]
17. Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer.
Vicier C; Ravi P; Kwak L; Werner L; Huang Y; Evan C; Loda M; Hamid AA; Sweeney CJ
Prostate; 2021 Jan; 81(1):50-57. PubMed ID: 32986884
[TBL] [Abstract] [Full Text] [Related]
18. Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis.
Yuan Z; Fernandez D; Dhillon J; Abraham-Miranda J; Awasthi S; Kim Y; Zhang J; Jain R; Serna A; Pow-Sang JM; Poch M; Li R; Manley B; Fink A; Naghavi A; Torres-Roca JF; Grass GD; Kim S; Latifi K; Hunt D; Johnstone PAS; Yamoah K
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):140-149. PubMed ID: 32651467
[TBL] [Abstract] [Full Text] [Related]
19. High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot.
Keam SP; Halse H; Nguyen T; Wang M; Van Kooten Losio N; Mitchell C; Caramia F; Byrne DJ; Haupt S; Ryland G; Darcy PK; Sandhu S; Blombery P; Haupt Y; Williams SG; Neeson PJ
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581061
[TBL] [Abstract] [Full Text] [Related]
20. Use of Aspirin and Statins in Relation to Inflammation in Benign prostate Tissue in the Placebo Arm of the prostate cancer Prevention Trial.
Hurwitz LM; Kulac I; Gumuskaya B; Valle JABD; Benedetti I; Pan F; Liu JO; Marrone MT; Arnold KB; Goodman PJ; Tangen CM; Lucia MS; Thompson IM; Drake CG; Isaacs WB; Nelson WG; De Marzo AM; Platz EA
Cancer Prev Res (Phila); 2020 Oct; 13(10):853-862. PubMed ID: 32581009
[TBL] [Abstract] [Full Text] [Related]
[Next]
